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Abstract 
Histone deacetylase (HDAC) inhibitors such as vorinostat (SAHA), valproic acid (VPA), 
romidepsin (FK-228), and LBH589 comprise a relatively new class of potent anticancer agents. 
The present study provides evidence for the potential of vorinostat to cause acquisition of MDR-
independent resistance in HCT116 colon tumor cells. This acquired resistance is moderate (2 to 
3-fold), is non-reversible, and correlates with the loss of responses typically seen with HDAC 
inhibitors, i.e. the loss of acetylation of the histones H2A, H2B, H3, and H4, the loss of the G2/M 
checkpoint activation, and the loss of caspase 3- and caspase 7-dependent apoptosis. This 
acquired resistance also associates with cross-resistance to the hydroxamate-class (LBH589 and 
JNJ26481585) and to the aliphatic acid-class (VPA) HDAC inhibitors but not to the benzamide-
class (MGCD0103) and the cyclic peptide-class (romidepsin) HDAC inhibitors. The herein 
described acquired HDAC inhibitor resistance is not due to altered HDAC and HAT activities 
and differs from that previously reported for romidepsin. 
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Introduction 
Vorinostat (suberoylanilide hydroxamic acid, SAHA) belongs to the continuously growing class 
of histone deacetylase (HDAC) inhibitors [1-3]. Pre-clinical studies with vorinostat have shown 
that its antiproliferative effects are associated with activation of the G2/M cell cycle checkpoint 
and upregulation of p21, with downregulation of cyclin D1, and with acetylation of numerous 
transcription factors (e.g. p53) and other proteins (e.g. HSP90, tubulin) [1]. In general, HDAC 
inhibitors result in the accumulation of acetylated histones and of non-histone proteins, and many 
of them exert strong antineoplastic activity. They also alter the gene expression pattern and 
thereby cause cell cycle arrest and apoptosis preferentially in tumor cells [4-8]. 
Resistance to an anticancer treatment, either present intrinsically in tumor cells or acquired 
during a treatment, is a frequently observed and persistent problem during cancer treatment. 
Acquired resistance is a particular problem, because tumors not only become resistant to the 
drugs originally used to treat them, but may also become cross-resistant to other drugs with 
different mechanisms of action. Mechanisms of resistance to HDAC inhibitors and their 
therapeutic implications have recently been reviewed [9]. In addition, the potential of HDAC 
inhibitors to cause drug resistance in tumor cells has recently become apparent. The HDAC 
inhibitor romidepsin (FK-228 or depsipeptide) has been shown to cause transient resistance by 
the reversible induction of multidrug resistance protein (MDR) expression in tumor cells and is to 
date the only HDAC inhibitor known to be substrate for multidrug resistance transporters [10, 
11]. Recently, we reported the generation of two MDR-independent, vorinostat-resistant sublines 
[12]: these were the DNA mismatch repair (MMR)-proficient HCT116ch3 colorectal 
adenocarcinoma cell line (supplemented with chromosome 3 harboring the wildtype copy of the 
MLH1 gene to compensate for the MLH1 gene truncating mutation present in the parental MMR-
deficient HCT116 cell line) and the MMR-deficient HCT116ch2 cell line (supplemented with the 
MLH1-irrelevant chromosome 2 for chromosome balance). Although a relationship between 
MLH1 expression and histone acetylation has been suggested [13, 14], this vorinostat-induced 
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resistance was independent of the presence or absence of MLH1 protein. Noteworthy, these 
vorinostat-resistant sublines were cross-resistant to the HDAC inhibitor trichostatin A but 
retained sensitivity to non-HDAC inhibitor-type anticancer agents. 
Using the parental HCT116 colorectal adenocarcinoma cell line, the present study was 
designed to (i) elucidate in more detail the mechanism(s) behind resistance induction by 
vorinostat, (ii) investigate a possible cross-resistance to some “second-generation” HDAC 
inhibitors, and (iii) exclude a possible effect of the presence of the extra chromosome in the 
respective cell lines on this type of acquired vorinosat resistance. Further evidence is provided 
that in HCT116 tumor cells vorinostat can lead to a multidrug resistance transporter-independent 
acquisition of resistance. This resistance correlates with the losses of histone acetylation, cell 
cycle attenuation, and apoptosis, but does not associate with altered HDAC and HAT activities. 
 
 
Materials and methods 
Drugs and chemicals 
Vorinostat (suberoylanilide hydroxamic acid SAHA; Alexis Biochemicals, Lausen, Switzerland) 
and valproic acid (VPA; Sigma, Buchs, Switzerland) were purchased. LBH589 (Novartis 
Pharmaceutical, Inc. Cambridge, MA), MGCD0103 (ALTANA Pharma-Nycomed, Byk-Gulden 
Street 2, Konstanz, Germany), and JNJ26481585 (J&J Pharmaceutical Research & Development, 
Beerse, Belgium) were provided. Romidepsin (FK-228, depsipeptide) was provided by 
Gloucester Pharmaceuticals, Cambridge, MA, USA. Stock solutions (stored at -20°C) were 
prepared in DMSO (vorinostat, LBH589, MGCD0103, JNJ26481585, romidepsin) or in H2O 
(VPA). 
 
Cell culture and generation of vorinostat-resistant sublines 
An HCT116 human colorectal adenocarcinoma cell line (American Type Culture Collection; 
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ATCC CCL 247) and a HeLa cervical carcinoma cell line (provided by Dr. G. Marra, Institute of 
Molecular Cancer Research, University of Zurich, Switzerland) were used. Both cell lines were 
cultured in IMDM-21980 (Invitrogen, Basel, Switzerland) containing 10% fetal calf serum 
(Oxoid, Basel, Switzerland) at 37ºC and in an atmosphere with 5% CO2 and 95% humidity. 
The respective sublines (hereafter designated as HCT116/VOR or HeLa/VOR) were 
generated by stepwise exposures of the cell lines to increasing concentrations of vorinostat, 
starting with 2 M vorinostat for both cell lines. Briefly, 100,000 cells seeded in cell culture 
flasks were treated with vorinostat on the next day. Forty-eight hours later, the vorinostat-
containing medium was exchanged for vorinostat-free medium, followed by incubation of the 
cells for another 6 days to allow recovery of the surviving cells and by harvesting of the cells by 
trypsinization. Cells were then transferred into new flasks, expanded to confluence, harvested, 
and re-seeded (100,000) in flasks. On the next day cells were treated with vorinostat and 
subjected to medium exchange, recovery, and harvesting as described. This protocol was repeated 
7 times, and for each cycle the concentration of vorinostat was increased, resulting in a 14-fold 
total increment for HCT116 (28 M) and a 35-fold for HeLa cells (70 M). A further increase in 
the selection pressure beyond these apparently maximal vorinostat concentrations failed to 
produce sufficient surving cells for cell culture expansion. 
The principle of selection was the clonal growth in the presence of increasing concentrations 
of vorinostat, on the basis that cells are altered by chronic vorinostat exposure in a way they 
acquire new features in an irreversible fashion. The growth rates of the cell lines and the 
respective sublines were calculated from the doubling times from one passage to the subsequent, 
averaged for a period of two months, and compared to one another. The level of resistance was 
determined right after the cells have been expanded to confluency after the last cycle by the 
clonogenic assay (these are the IC50 values presented throughout the paper) and was periodically 
monitored by the clonogenic assay against the parental cell line. The level of resistance was 
maintained over a period of at least 6 months even when cultured in the absence of the selection 
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pressure of vorinostat. When seeded sparsely on culture plates, the cell lines and the sublines 
formed well-defined individual colonies. 
 
Drug sensitivity assays 
Sensitivity of cells to the HDAC inhibitors tested herein was assessed by clonogenic and growth 
inhibition assays. In a typical clonogenic assay setting, 600 cells in medium were plated onto 60 
mm cell culture dishes, followed by drug addition on the next day. Cells were cultured for 
another 7 days to allow colony formation, fixed with 25% acetic acid in ethanol, and stained with 
Giemsa. Colonies of at least 50 cells were scored. Each experiment was performed at least 3 
times in triplicate cultures. The relative colony formation (% clonogenic survival) was plotted 
against the drug concentrations and the IC50 concentrations were calculated by linear 
extrapolation. For growth inhibition, 50,000 cells were plated into 35mm culture dishes and 
treated with vorinostat (1 M, 2 M, 5 M, 10 M). Cells were harvested by trypsinization at 
multiples of 24 hours after treatment and counted using a hematocytometer. In addition, Trypan 
blue-inclusion was used to monitor drug-induced necrosis. Cells were treated for 24 hours with 5, 
10 or 20 M vorinostat, harvested by trypsinization after another 24-hour incubation, and 
resuspended in PBS containing 0.2% Trypan blue. Cells were inspected and categorized using a 
hematocytometer. Vital (Trypan blue-excluding) cells appear bright, and necrotic (Trypan blue-
including) cells appear blue under the microscope. 
 
Microscopy 
Cells (200,000) were plated into 35 mm cell culture dishes, grown to 70% confluence, and then 
grown for another 24 hours without (controls) or with 10 M vorinostat. Bright-field images were 
taken using a microscope (Leica DM-IL; Leica Microsystems, Heerbrugg, Switzerland) equipped 
with a photocamera (Leica DC-300F; Leica Microsystems). 
 
6 
Immunoblot analysis 
All the experiments for immunoblot analysis and for cell cycle and apoptosis analyses (described 
below) were carried out the way that all the cultures were subconfluent at the time of analysis in 
order to avoid undesired effects due to e.g. contact inhibition. Immunoblot analysis was used to 
monitor protein expression and post-translational modifications of proteins (phosphorylation, 
acetylation). After the cells have grown to 70% confluence in 60 mm dishes, they were treated 
with HDAC inhibitors and collected at various time points after treatment, washed in PBS, and 
lysed for immunoblot analysis performed following standard protocols. Briefly, 20 g protein 
was separated using 10% or 15% SDS-PAGE, followed by the blotting onto a polyvinylidene 
difluoride membrane (Amersham Biosciences, Otelfingen, Switzerland), and the detection by the 
specific primary antibodies and the respective secondary, horseradish peroxidase-conjugated anti-
mouse (M15345; Transduction Laboratories, Lexington, KY) or anti-rabbit (7074; Cell Signaling; 
BioConcept, Allschwil, Switzerland) antibodies. The following primary antibodies were used 
(Cell Signaling, if not specified otherwise): Acetyl-H2A (2576), acetyl-H2B (2575), acetyl-H3 
(9671), acetyl-H4 (2594), acetyl-p53 (ab37318; Abcam, Cambridge, UK), acetyl-tubulin (T-
6793; Sigma), acetyl-HSP90 (ABIN233817; antibodies-online, Aachen, Germany), MDR (sc-
13131; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), MRP-1 (sc-18835; Santa Cruz 
Biotechnology), HDAC1 (2062), HDAC2 (05-815; Upstate, Lake Placid, NY), HDAC3 (2632), 
HDAC4 (2072), HDAC5 (2082), HDAC6 (2162), HDAC7 (2862), full-length and cleaved 
caspase-3 (9662, 9661), full-length and cleaved caspase-7 (9492, 9491), full-length and cleaved 
PARP-1 (9542, 9541), Bax (2772), Bak (3792), Bid (2002), Bim (4582), Bik (4592), Bok (4521), 
Bcl-2 (2872), Bcl-xL (2762), survivin (Pro-2233; ProSci Inc., Poway, CA), XIAP (2042), Mcl-1 
(4572), p21 (2946), p27 (2552), p53 (sc-6243; Santa Cruz Biotechnology), cyclin B1 (4135), 
cyclin D1 (2926), cyclin D3 (2936), cyclin E2 (4132), thioredoxin (2285), TBP-2/VDUP-1 (sc-
33099; Santa Cruz Biotechnology or 40-3700; ZYMED, Invitrogen, Carlsbad CA), HSP90 (sc-
7947; Santa Cruz Biotechnology), and phospho-HSP27 (2401). Anti-mouse -actin (A5441; 
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Sigma) or anti-rabbit -tubulin (2148, Cell Signaling) were used as sample loading controls. 
Complexes were visualized by enhanced chemiluninescence (Amersham Biosciences) and 
autoradiography. 
 
HDAC immunoprecipitation and determination of histone deacetylase and histone 
acetyltransferase activities 
Immunoprecipitation of HDAC1 (2062; Cell Signaling; BioConcept, Allschwil, Switzerland), 
HDAC2 (05-814; Upstate), HDAC3 (05-813; Upstate), and HDAC6 (07-732; Upstate) was done 
following standard protocols provided by the manufacturers from total cell extracts (lysates) of 
the vorinostat-sensitive HCT116 cell line and the vorinostat-resistant HCT116/VOR subline 
using Protein A agarose beads (16-266; Upstate) and the respective immunoprecipitation-
qualified antibodies. Nuclear extracts of the sensitive HCT116 cell line and the resistant 
HCT116/SAHA subline were produced using the TransFactor Extraction Kit and following the 
manufacturer’s protocol (631921, Clontech, Takara Bio Europe, Saint-Germain-en-Laye, 
France). Protein concentration of nuclear and total cell extracts and the samples was determined 
by the BCA Protein Assay Kit (23227; Pierce, Perbio Science, Lausanne, Switzerland). 
The HDAC and histone acetyltransferease (HAT) enzymatic activities were determined in 
total or nuclear cell extracts using the colorimetric HDAC activity assay Kit (ab1432, Abcam), 
the fluorometric HDAC assay Kit (17-356; Upstate, Lake Placid, NY)), and the fluorescent HAT 
activity assay Kit (56100, Active Motif Europe, Rixensart, Belgium). Measurements were made 
with a SpectraFluor Plus Reader (TECAN AG, Switzerland). The assays, including all standard 
assays,were performed according to the protocols provided by the manufacturers. All the activity 
assays were performed in two independent settings under conditions where neither the sample 
enzymatic activity, the substate, nor the assay incubation time were rate-limiting. Enzymatic 
activities were standardized, i.e. expressed as units or counts per amount protein. 
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Cell cycle and apoptosis analyses by flow cytometry 
Analyses of cell cycle profiles (propidium iodide incorporation in the DNA) and apoptosis 
(TUNEL DNA fragmentation) were performed by flow cytometry on a FACSCalibur flow 
cytometer (BD Biosciences; Allschwil, Switzerland) with CELLQuest software (BD 
Biosciences). Data analyses for cell cycle distribution and apoptosis were performed on linear PI 
histograms using the mathematical software ModFit LT 2.0 (Verity Software House; Topsham, 
ME, USA). For sample preparation, synchronized (2 mM hydroxyurea for 14 hours) cells were 
grown to 70% confluence in 60 mm dishes and treated with 15 M vorinostat. At different time 
points, adherent and floating cells were harvested, washed in PBS, and fixed with ice-cold 70% 
ethanol. For cell cycle analysis, cells were washed in PBS after removal of the ethanol by 
centrifugation, stained in 1ml staining solution (50 g/ml of propidium iodide and 100 U/ml 
RNAse A in PBS) by incubation at room temperature for 45 minutes in the dark, and then washed 
in PBS. For TUNEL apoptosis analysis, following ethanol removal the cells were washed in PBS, 
resuspended in the TUNEL reaction-mix, and incubated at 37°C for 90 minutes according to the 
manufacturer’s protocol (In Situ Cell Death Detection Kit, Fluorescein, Roche Diagnostics, 
Rotkreuz, Switzerland). 
 
Statistical analysis 
The mean ± SD values were calculated. A p value less than 0.05 is considered statistically 
significant (paired, two-tailed Student’s t test). 
 
 
Results 
Generation of the vorinostat-induced and stable vorinostat-resistant HCT116 subline 
A vorinostat-induced (resistant) subline (hereafter referred to as HCT116/VOR) was 
generated by stepwise exposures of the parental HCT116 human colorectal adenocarcinoma cell 
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line to increasing concentrations of vorinostat. Clonogenic assay data demonstrated that the 
vorinostat-induced subline was 2-fold resistant (p < 0.001) to vorinostat as compared to the 
corresponding parental HCT116 cell line (Fig. 1a). The respective IC50-values were 1.32 ± 0.14 
M for the resistant HCT116/VOR subline and 0.67 ± 0.08 M for the (sensitive) parental 
HCT116 cell line. The resistant subline exhibited a growth rate comparable to that of the parental 
HCT116 cell line, as the doubling times were 22.6 ± 0.9 hours for HCT116 and 23.5 ± 1.2 hours 
for HCT116/VOR. Likewise, vorinostat inhibited growth of the vorinostat-resistant 
HCT116/VOR subline less efficiently than the vorinostat-sensitive HCT116 cell line (Fig. 1b). 
For instance, 96 hours post treatment the respective values were 5-fold (1 M vorinostat), 8-fold 
(2 M), 4-fold (5 M), and 11-fold 10 (M). This HCT116/VOR subline maintained resistance to 
vorinostat for over 30 passages (at least 6 months) even when cultured in medium without 
presence of the selection pressure of vorinostat. This indicates that vorinostat can induce stable, 
i.e. non-reversible, resistance in HCT116 tumor cells. 
Consistent with the clonogenic and growth inhibition assay data, bright-field microscopy for 
HCT116 cultures (Fig. 1c, d) showed that vorinostat treatment produced a larger reduction in the 
number of cells and more dramatic morphological changes (e.g. rounding-up) in cultures with the 
parental cell line than in those with the vorinostat-resistant subline (a large fraction retains its 
fibroblast-like shape). No morphological differences between the parental and vorinostat-resistant 
(untreated) control cultures were apparent. 
 
Reduced histone acetylation in the vorinostat-resistant subline 
One result of the activity of HDAC inhibitors is the accumulation of acetylated histones. It was 
determined whether the vorinostat-induced resistance with the HCT116/VOR subline correlated 
with loss of histone acetylation. Immunoblot data showed that 15 M vorinostat produced 
acetylation of the histones H2A, H2B, H3, and H4 in the parental cell line but not in the resistant 
subline (Fig. 2a). p53, tubulin, and HSP90 can also be substrates for HDACs. Vorinostat (15 M) 
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produced  increases in acetyl-p53 and acetyl-tubulin, but these increases were similar in the 
parental HCT116 and the resistant HCT116/VOR cells (Fig. 2a). The levels of acetylated HSP90 
were also comparable in both cultures and were not affected by vorinostat. 
These results indicate that acquired vorinostat resistance correlates with loss of histone 
acetylation but not with alterations in the levels of acetylated p53, tubulin, and HSP90. 
 
Lack of HDAC overexpression and of MDR expression in the vorinostat-resistant subline 
There are several mechanisms that could give rise to reduced accumulation of acetylated histones 
seen with the vorinostat-resistant subline. These include the increased availability of HDAC 
enzymes due to the overexpression of one or more HDACs or the reduced availability of 
intracellular vorinostat due to the expression of multidrug resistance efflux transporters. 
However, immunoblot analysis showed that higher levels of HDAC1, HDAC3, HDAC5, or 
HDAC6, were not found in the vorinostat-resistant subline as compared to its sensitive 
counterpart (Fig. 2b). HDAC4 and HDAC7 were not detected in both cultures. Likewise, neither 
the MDR nor the MRP-1 (multidrug resistance-associated protein 1) transporters were expressed 
in the parental or resistant cell lines (Fig. 2c). 
These results indicate that acquired vorinostat resistance does neither correlate with 
expression of these multidrug resistance transporters nor with overexpression of HDACs. 
 
Histone acetyltransferase and histone deacetylase activities 
Resistance could arise through alterations in the enzymatic activities of HATs and HDACs. It 
was determined whether the resistant subline exhibits HAT and HDAC activities that differ from 
those of the sensitive cell line; i.e. whether the HAT activity was lower and/or the HDAC activity 
was higher in the resistant cells. Nuclear HAT activity was similar in the resistant HCT116/VOR 
subline and in the sensitive HCT116 cell line (Fig. 3a). The enzymatic activities of HDAC1, 
HDAC2, HDAC3, and HDAC6 in the resistant HCT116/VOR subline and the sensitive HCT116 
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cell line were comparable and were comparably reduced by vorinostat (Fig. 3b). According to the 
activities of each individual HDAC tested, the overall HDAC activity was not different in both 
cultures (Fig. 3c) and was not differentially affected by vorinostat (Fig. 3d) and by VPA (data not 
shown). 
These results indicate that the sensitive and the resistant cells are not different with respect to 
the HAT and HDAC activities. 
 
Loss of apoptosis and G2/M cell cycle arrest in the vorinostat-resistant subline 
The accumulation of acetylated histones in response to HDAC inhibitors causes the decondensing 
of chromatin, and this facilitates the expression of genes, leading to an arrest of the cell cycle at 
the G2/M transition and to apoptosis. Accordingly, it was determined whether the loss of histone 
acetylation seen in the vorinostat-resistant subline correlated with reduced activation of this cell 
cycle checkpoint and of apoptosis. Quantitative analysis of the primary data derived from flow 
cytometry analysis demonstrated that the fraction of cells accumulated at the G2/M checkpoint 
transition was 2.5-fold smaller in the HCT116/VOR subline than in the parental HCT116 cell line 
following treatment with 15 M vorinostat (Fig. 4a). 
Immunoblot analysis (Fig. 4b) showed that 15 M vorinostat failed to produce proteolytic 
cleavage of the precursors of caspase-3 and caspase-7 and of the PARP-1 precursor in the 
resistant subline as compared to its sensitive counterpart, and TUNEL analysis revealed that the 
resistant subline showed a 4-fold lower DNA fragmentation (Fig. 4c). The fraction of Trypan 
blue-including cells was nearly the same in untreated cultures and in cultures treated with 5 or 10 
M vorinostat (slightly higher with 20 M). But there is no difference between the vorinostat-
sensitive cell line and vorinostat-resistant subline (Fig. 4d), indicating that reduced susceptibility 
to necrosis does not account for vorinostat-induced resistance. 
These results indicate that acquired vorinostat resistance in HCT116 cells correlates with 
both loss of the G2/M checkpoint and loss of caspase-dependent apoptosis. 
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 Expression of HDAC inhibitor-responsive and cell cycle and apoptosis control proteins 
HDAC inhibitors affect the expression of a variety of genes. Among those are pro-apoptotic Bax 
and anti-apoptotic Bcl-2, and the cell cycle regulators p21, p53, and the cyclins B1, D1, D3, and 
E. It was determined whether in the vorinostat-resistant cells the expression of Bax, p21, and p53 
was downregulated and that of Bcl-2 and the cyclins was upregulated. Immunoblot data (Fig. 5) 
demonstrated that expression levels of p21 (and to a lesser extent p27) were increased upon 
treatment with 15 M vorinostat; but this was to a similar extent in the resistant and the sensitive 
cells. The protein levels of Bax, Bcl-2, and p53 were also similar: Bax and p53 did not change as 
a function of time after treatment with vorinostat, whereas that of Bcl-2 decreased. Likewise, the 
expression levels of the cyclins B1, D1, D3, and E2 in the resistant subline did not differ from 
that in the sensitive cell line; the expression of B1 and D1 was downregulated 24 hours after 
vorinostat treatment, whereas the cyclins D3 and E2 were upregulated. Moreover, the basal 
expression level of anti-apoptotic survivin, XIAP, and Mcl-1 was not increased and that of pro-
apoptotic Bid, Bim, Bik, and Bok was not decreased in the vorinostat-resistant subline as 
compared to the vorinostat-sensitive cell line. In both cultures, the protein level of XIAP was 
decreased, those of Mcl-1 and Bim were increased, and those of Bid, Bik, Bok, and survivin were 
unchanged in response to vorinostat. 
Anti-apoptotic thioredoxin, a protein that scavenges reactive oxygen species, which can be 
produced by HDAC inhibitors, was not overexpressed in the resistant subline, and thioredoxin-
binding protein 2 (TBP-2) that downregulates thioredoxin expression was not detected. The 
levels of HSP90 and phosphorylated HSP27, two heat shock proteins with cytoprotective 
functions and reported to be downregulated by HDAC inhibition remained unaffected by 
vorinostat in both cultures. The base level of all these proteins was comparable in the vorinostat-
sensitive and the vorinostat-resistant cells. 
These results indicate that resistance to apoptosis and to cell cycle attenuation in the 
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vorinostat-induced subline is not reflected by detectable alterations in the expression of a large 
number of proteins usually affected by HDAC inhibitors and relevant to the control of these 
processes. 
 
Cross-resistance to other HDAC inhibitors 
It was determined whether the HCT116/VOR subline was cross-resistant to other HDAC 
inhibitors. A statistically significant, 2 to 3-fold cross-resistance was found with VPA (Fig 6a), 
LBH589 (Fig 6b), JNJ26481585 (Fig 6c), but not with MGCD0103 (Fig 6d) and romidepsin (Fig. 
6e). The respective IC50 values are presented (Table 1). Accordingly, treatment with VPA, 
LBH589 or JNJ26481585 did not result in accumulation of acetylated histones and cleaved 
PARP-1 in the vorinostat-resistant subline, while the ability to accumulate acetylated histones 
and to cleave PARP-1 was maintained in response to treatment with MGCD0103 and romidepsin. 
Acetylated tubulin was essentially expressed to comparable levels in the vorinostat-resistant 
and the vorinostat-sensitive cells. It also looks as though LBH589 and JNJ26481585, in contrast 
to VPA, MGCD0103, and romidepsin produced an increase in acetyl-tubulin to some extent. 
Acetyl-HSP90 was present in both cultures to the same extent and was not affected by treatment 
with each one of the HDAC inhibitors. 
These results indicate that acquired resistance to vorinostat is accompanied by cross-
resistance to at least some HDAC inhibitors, and that cross-resistance does not go along with 
alterations in the level of acetylated tubulin and acetylated HSP90 
 
No acquisition of resistance by vorinostat in HeLa cells 
In order to see whether resistance induction by vorinostat could also be seen with HeLa cells, the 
same protocol was applied to this tumor cell line. However, this protocol did not produce a 
vorinostat-resistant HeLa/VOR subline and neither loss of accumulation of acetylated histones 
nor loss of apoptosis were observed in the subline (data not shown). This indicates that HeLa 
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cells are not susceptible to resistance acquisition by vorinostat. 
 
 
Discussion 
The antineoplastic activity of HDAC inhibitors is an unquestionable property of these 
compounds. But recent studies have shed some light on another aspect of HDAC inhibitors, 
namely their association with resistance and their potential to cause resistance acquisition in 
tumor cells [9-12]. From the present study with vorinostat the following conclusions may be 
drawn. First, expanding on a previous study [12], this one provides further evidence that 
vorinostat has the potential to cause stable and MDR-independent HDAC inhibitor resistance in 
vitro. Second, this acquired resistance clearly correlates with the losses of histone acetylation, cell 
cycle checkpoint activation, and apoptosis susceptibility. Third, this resistance cannot be 
explained by altered expression of selected HDACs, by altered HDAC and HAT activities, and 
by failure to induce p21 expression. Fourth, cross-resistance was found to VPA and 
hydroxamate-class HDAC inhibitors, but not to benzamide- and cyclic peptide-class HDAC-
inhibitors. Fifth, using the parental HCT116 colorectal adenocarcinoma cell line, this study rules 
out the possibility that vorinostat resistance acquisition arises as a consequence of the presence of 
extra chromosomes in the chromosome-supplemented HCT116 cell lines that have been used in 
the previous study [12]. 
The potential of HDAC inhibitors to cause resistance has recently become apparent. Two 
studies have shown that the HDAC inhibitor romidepsin induced a reversible, up to 10’000-fold 
resistance in a variety of tumor cells due to the inducible and transient expression of MDR and 
MRP-1 [10, 11]. However, the herein described vorinostat-induced resistance differs from that 
with romidepsin in several ways: it is non-reversible (i.e. was maintained even in the absence of 
vorinostat in the culture medium), moderate (2-fold), and cannot be explained by the efflux of 
vorinostat through the multidrug resistance transporters MDR and MRP-1. The latter is in line 
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with the observations that MDR-mediated resistance is usually by far larger than 2-fold. Our 
results thus suggest that resistance acquisition by vorinostat and by romidepsin are based on the 
different mechanisms. Apparently, there is a selection pressure for vorinostat, beyond which cells 
are no longer vital. The observation that this virtually maximal vorinostat concentration (28 M) 
is substantially higher than the IC50 (1.3 M) for the vorinostat-resistant HCT116/VOR subline 
may mean that there is an at least partial reversal of vorinostat resistance after removal of the 
vorinostat selection pressure in HCT116 cells. A complete reversal (from 70 M selection 
pressure to IC50 1.3 M) may be suggested for the HeLa cells. 
Acetylation of histones is one hallmark of HDAC inhibitor-induced cellular responses. 
Accordingly, acquired vorinostat resistance correlated with failure to acetylate the four histones. 
Reduced intracellular availability of vorinostat due to alterations in efflux or influx transporters is 
unlikely: MDR transporters are not involved and there is no evidence that vorinostat is taken up 
by processes other than by diffusion. In addition, failure to acetylate histones may also arise from 
overexpressed or overactivated HDACs or from reduced HAT activity [15], but no lower HAT 
activity and no higher activity of individual HDACs (HDAC1, HDAC2, HDAC3, HDAC6) and 
of overall HDAC activity were found in the vorinostat-resistant subline. A previous study has 
shown that a truncating mutation in the HDAC2 gene confers resistance to the HDAC inhibitor 
trichostatin A [16].  
In addition to histones, non-histone proteins such as tubulin, p53, and HSP90 are also 
acetylated as a result of HDAC inhibitors [17-19]. Acetylated tubulin associates with tumor 
growth inhibition and acetylated p53 promotes p53-dependent gene transcription [19, 20]. 
Acetylated HSP90 is inactive and seems to promote apoptosis [21]. It was reasoned that the 
vorinostat-resistant cells have lower levels of acetylated tubulin, p53, or HSP90. However, 
vorinostat induced increases in acetylated p53 and tubulin in both the sensitive and resistant cells 
to a similar extent, and the levels of acetylated HSP90 remainded unchanged. This indicates that 
vorinostat resistance was not accompanied by reduced acetylation of p53, tubulin, and HSP90. 
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The therapeutic effect of vorinostat is based on its ability to produce cell cycle arrest and 
apoptotic cell death. Vorinostat targets the G2/M checkpoint in HCT116 tumor cells and the 
antitumor effect of vorinostat may be due to induction of polyploidy [22]. The present study 
shows  that the activation of the G2/M checkpoint was run over and the induction of caspase-
dependent apoptosis was markedly reduced in the vorinostat-resistant subline. In the vorinostat-
resistant subline, the reduced susceptibility to apoptosis seems to be linked to the reduced levels 
of histone acetylation. It was occasionally observed that vorinostat concentrations, which induced 
(reduced with respect to the sensitive counterpart) apoptosis in the vorinostat-resistant subline, 
also showed (reduced) accumulation of acetylated histones, but accumulation of acetylated 
histones without apoptosis was never observed. It seems that, at least for vorinostat, apoptosis 
does not occur without histone acetylation, meaning that histone acetylation is required for 
vorinostat-induced apoptosis. 
It was examined whether alterations in the expression of a number of cell cycle-relevant 
genes account for the observed loss of the G2/M checkpoint activation. However, alterations in 
expression of cell cycle-relevant genes were not observed; p21 expression, which plays a key role 
in the cytostatic effect of vorinostat [22], and p27 expression were observed in both the resistant 
and the parental cell line. Cyclin D1 is an HDAC inhibitor-responsive gene and is downregulated 
by vorinostat in tumor cells [23]. Indeed, vorinostat produced downregulation of the cyclins B1 
and D1, but this was also seen in the resistant cells. Likewise, the HDAC inhibitor-responsive 
cyclins D3 and E2 were also upregulated in both cultures.  
Reduced apoptosis in the vorinostat-resistant cells may be due to loss of pro-apoptotic Bax 
Bak, Bid, Bim, Bik, and Bok; to upregulation of anti-apoptotic Bcl-2, Bcl-xL [24], Mcl-1, XIAP, 
and survivin; or to altered expression of HSP90 and phosphorylated HSP27, two heat shock 
proteins downregulated by HDAC inhibitors [25, 26]. This was, however, not the case, as the 
expression of these proteins was similar in the vorinostat-resistant and in the parental (vorinostat-
sensitive) cells. Likewise, acquired vorinostat resistance cannot be explained by increased 
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thioredoxin levels in these cells. Thioredoxin scavenges reactive oxygen species produced in 
response to vorinostat and MS-275 [7], and this results in inhibition of oxidative stress-induced 
cell death [27]. 
An important finding from this study is that the vorinostat-resistant cells show cross-
resistance to other “first-” and “second-generation” HDAC inhibitors, associated with failure to 
acetylate histones and to apoptose in response to these HDAC inhibitors. This is not only within a 
particular class of HDAC inhibitors (the hydroxamates LBH589, JNJ26481585, TSA) but also 
among members of different classes of HDAC inhibitors (e.g. the aliphatic acid VPA). A 
particularly striking observation was that the vorinostat-resistant cells retained sensitivity and 
susceptibility to histone acetylation and apoptosis to the HDAC inhibitors MGCD0103 and 
romidepsin. The benzamide head group in MGCD0103 and the specific conversion of the cyclic 
peptide romidepsin into its active form [28] seems to make the difference, as opposed to the 
hydroxamic acid (vorinostat, LBH589, JNJ26481585, TSA) or the acid (VPA) head groups. The 
absence of cross-resistance to these two HDAC inhibitors and the previously reported absence of 
cross-resistance to “classic” (non HDAC inhibitor-type) anticancer agents in the vorinostat-
resistant cells may be of clinical interest [12]. Cross-resistance does neither go along with lower 
levels of acetylated tubulin nor with reduced levels of acetylated HSP90. The putative increase in 
acetylated tubulin in response to LBH589 and JNJ26481585 (in contrast to VPA, MGCD0103, 
and romidepsin) seems to go along with the notion that these two HDAC inhibitors are inhibitors 
of the tubulin deacetylase site of HDAC6. In addition, the finding that HDAC6 activity is 
comparable in the vorinostat-resistant and the vorinostat-sensitive cells goes along with the 
comparable level of acetylated tubulin in both cultures. 
It is to note that the vorinostat concentrations required to select for vorinostat resistance in 
vitro are in the range of those measured in the serum of patients treated with therapeutic doses in 
Phase I/II studies [29]. This may mean that the generation of vorinostat-resistant cells might also 
occur in patients. Somehow surprising is that in the present study’s experimental setting the 
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typical responses to vorinostat, i.e. acetylation of histones and induction of cell cycle arrest and 
apoptosis, are observed at relatively high vorinostat concentrations (15 M), i.e. higher than those 
required to abrogate clonogenicity (IC99 around 2 M). In addition, the acetylation of histones by 
vorinostat was detected at later time points than usual. It is to note that the vorinostat-induced 
responses were essentially also observed with 5 M but to a lesser extent. 
Despite the clear-cut correlation between acquired vorinostat resistance and the loss of some 
molecular and cellular responses typically seen with HDAC inhibitors, the molecular basis of this 
resistance is still not understood. For instance, it is unclear why the effects of vorinostat on 
acetylation of non-histone proteins (e.g. tubulin, p53, HSP90) and in particular on the expression 
of HDAC inhibitor-responsive genes assessed herein (e.g. p21) are similar in the parental 
(sensitive) and the resistant cells. It is also unclear how failure to histone acetylation arises, 
whether this failure arise from other HDAC inhibitor sequestration or detoxification systems or 
from impaired transport of HDAC inhibitors into the nucleus, whether DNA methylation, a 
biochemical process cooperating with histone (de-)acetylation and involved in gene silencing 
[30], is altered at promoter sites, what the role of cellular polyamines [31] may be, and why 
resistance acquisition was not observed with the HeLa cervical cancer cells. Appreciating the 
complexity of the molecular effects of HDAC inhibitors and the mechanisms of drug resistance, 
it is likely that not one particular mechanism but a rather multifactorial alteration of different cell 
regulating pathways underlies vorinostat resistance. This mechanism probably arises due to the 
epigenetic targeting by the HDAC inhibitors. 
Taken together this study provides further evidence for the potential of vorinostat to cause 
acquisition of HDAC inhibitor resistance in HCT116 tumor cells. This acquired HDAC inhibitor 
resistance clearly correlates with the loss of important molecular responses typically seen with 
HDAC inhibitors and being responsible for the cytotoxic effect of these compounds. 
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Table 1: IC50 values representing cross-resistance of HCT116 and HCT116/VOR cells determined by the clonogenic assay 
 VPA (mM) JNJ26481585 (nM) LBH589 (nM) MGCD0103 (nM) romidepsin (nM) 
HCT116 1.25 ± 0.11 6.00 ± 1.00 6.27 ± 1.32 241 ± 33 1.07 ± 0.10 
HCT116/VOR 2.40 ± 0.13 17.30 ± 0.95 14.4 ± 1.10 252 ± 52 1.10 ± 0.10 
Fold difference* 1.92 2.88 2.30 1.04 1.03 
p values p < 0.001 (n=3) p < 0.001 (n=3) p < 0.002 (n=3) p = 0.782 (n=3) p = 0.716 (n=3) 
*Ratio of IC50 values of HCT116/VOR and HCT116 
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Legends for figures 
 
Fig.1. The effect of the HDAC inhibitor vorinostat (VOR) on clonogenic survival (a) and 
growth inhibition (b) of the HCT116 colon tumor cell line and its respective subline 
(HCT116/VOR, dashed line) generated by stepwise exposures of the HCT116 cells to increasing 
concentrations of vorinostat. For the clonogenic assay, cultures were treated with vorinostat for 8 
days, and colonies were fixed, stained with Giemsa, and counted (data points are the mean ± SD 
of at least 3 independent experiments). For the growth inhibition assay, vorinostat-sensitive cells 
(block columns) and vorinostat-resistant cells (grey columns) treated with various concentrations 
of vorinostat (numbers atop the columns, given in M) were harvested and counted at multiples 
of 24 hours post treatment. Data (mean ± SD of two independent experiments) are presented as 
relative growth (ratio of the number of cells at a given time point and number of cells initially 
plated). Representative bright-field images of vorinostat-sensitive HCT116 (c) and vorinostat-
resistant HCT116/VOR (d) control cultures and the respective cultures captured 24 hours after 
treatment with 10 M vorinostat (c’, d’): a large fraction of vorinostat-resistant cells retain their 
fibroblast-like shape, whereas the vorinostat-sensitive parental cells show a round-up shape and 
substantially decrease in number (magnification is 20X and the scale bar equals 50 m). 
Fig. 2. Expression of acetylated histones, acetyl-tubulin, acetyl-p53, and acetyl-HSP90 (a), of 
HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, and HDAC7 (b), and of the multidrug 
resistance protein MDR and the multidrug resistance associated protein MRP-1 (c) as a function 
of time after treatment with 15 M vorinostat (VOR) in the vorinostat-sensitive (parental) 
HCT116 cell line and the vorinostat-resistant HCT116/VOR subline. Cells were treated with 15 
M vorinostat and lysed at the time points indicated. Proteins were separated by PAGE analysis 
and blotted, and complexes were detected by chemiluminescence and autoradiography. Positive 
control lysates for MRP-1 (A549, sc-2413, Santa Cruz Biotechnology Inc.) and MDR (MES-
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SA/Dx5A549, sc-2284, Santa Cruz Biotechnology Inc.) were also loaded (center lanes in c). -
actin and -tubulin served as sample loading controls. Representative of 2 independent data sets. 
Fig. 3. HAT and HDAC activities determined by in vitro assay kits. (a), HAT activity expressed 
as AFU (arbitrary fluorescence unit) per ng nuclear extract protein from (sensitive) parental 
HCT116 and resistant HCT116/VOR cells; also shown are the positive (recombinant p300 
catalytic domain) and the negative (recombinant p300 catalytic domain plus 15 M of the HAT 
activity quencher anacardic acid) assay controls. (b), HDAC activity of individual HDAC1, 
HDAC2, HDAC3, and HDAC6 expressed as counts per g HDAC from HCT116 (black 
columns) and HCT116/VOR (white columns) extracts. (c), Overall HDAC activity expressed as 
optical density (OD) per g of nuclear extract protein from parental HCT116 and resistant 
HCT116/VOR cells; also shown are the posititve (HeLa nuclear extract) and the negative (Hela 
nuclear extract plus 20 M trichostatin A) assay controls. (d), Overall HDAC activity expressed 
as the relative OD (percentage of untreated controls) of nuclear extracts from parental HCT116 
and resistant HCT116/VOR cells as a function of treatment with vorinostat (VOR). Mean ± SD of 
2 independent experiments. 
Fig. 4. (a), Cell cycle response of the vorinostat-sensitive parental HCT116 cell line and the 
vorinostat-resistant HCT116/VOR subline as a function of time after treatment with 15 M 
vorinostat (VOR). Quantitative representation (mean ± SD of 2 independent data sets) of the 
percentage of cells accumulated in the different phases of the cell cycle: G1 (gray bars), S-phase 
(white bars), and G2/M (black bars). Hydroxyurea-synchronized cells were treated with 15 M 
vorinostat, harvested, fixed, stained with propidium iodide, and analyzed by flow cytometry. (b, 
c), Effect of vorinostat on apoptosis in the parental cell line HCT116 and the vorinostat-resistant 
subline HCT116/VOR. Cells were either treated with vorinostat 15 M vorinostat and analyzed 
for proteolytic cleavage of the full-length precursors of PARP-1 (116 kD), of caspase-3 (35 kD), 
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and of caspase-7 (35 kD) into their respective cleaved fragments (86 kD, 17 kD, 17 kD) by 
immunoblotting (b), or treated with 20 M vorinostat and analyzed for (TUNEL)-DNA 
fragmentation by flow cytometry (c). (d), Effect of 5, 10 or 20 M vorinostat on necrosis in the 
parental HCT116 cell line and the vorinostat-resistant subline HCT116/VOR. Each data set is a 
representative data of 2 independent experiments. 
Fig. 5. Expression of cell cycle and apoptosis control proteins and other proteins possibly 
affected by HDAC inhibitors as a function of time after treatment with 15 M vorinostat (VOR) 
in vorinostat-sensitive parental (HCT116) and vorinostat-resistant (HCT116/VOR) cells. Cells 
were treated and lysed at the time points indicated. Proteins were separated by PAGE analysis 
and immunoblotted, and complexes were detected by chemiluminscence and autoradiography. -
actin was used as the sample loading control. Data are representatives of at least 2 independent 
data sets. 
Fig. 6. The effect of the HDAC inhibitors valproic acid VPA (a), JNJ26481585 (b), LBH589 
(c), MGCD0103 (d), and romidepsin (e) on the clonogenic survival (left panel) and on the 
proteolytic cleavage of PARP-1, and on the acetylation of the histones H3 and H4 (right panel) 
and the non-histone proteins tubulin and HSP90 in the (sensitive) parental HCT116 cell line and 
the resistant HCT116/VOR subline. Data points are the mean ± SD of at least 3 independent 
experiments (clonogenic assay). Representative of 2 independent data sets (immuno blotting). 
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